Bioavailability enhancers

Patent 5126348 Issued on June 30, 1992. Estimated Expiration Date:

September 26, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Inventor

McMurray, William H.

Application

No. 412795 filed on 09/26/1989

US Classes:

514/263.32, Nitrogen containing hetero ring in the perservative, stabilizer, or additional active ingredient514/356C=O in a C(=O)O group (e.g., nicotinic acid, etc.)

Examiners

Primary: Friedman, S. J.

Attorney, Agent or Firm

Greenlee and Winner

International Classes

A61K 031/44
A61K 031/52

Abstract

Vasodilators and theophylline.

Other References

EPO Publication 106,335, published Apr. 25, 1984
Ther, L. and Winne, D., (1971), "Drug Absorption", pp. 57-69
Cadwallader, D. E., (1971), Biopharmaceutics and Drug Interactions, (Roche Laboratories, Nutley, N.J.), p. 53
Cadwallader, D. E., (1971), Biopharmaceutics and Drug Interactions, (Roche Laboratories, Nutley, N.J.), p. 108
McLean, A. J., (1978), Clin. Pharmacol. Ther., 24:5-10
Schneck, D. W. and Vary, J. E., (1984), Clin. Pharmacol. Ther., 35:447-453
Condorelli, L., (1964), in Niacin in Vascular Disorders and Hyperlipemia, R. Altschul (ed.), pp. 162-164. (See Ref. O)
Svedmyr, N. et al., (1970), in Metabolic Effects of Nicotinic Acid and its Derivatives, K. F. Gey and L. A. Carlson (eds.), Hans Huber Pub., pp. 1085-1098
Grigoleit, H.-G. et al., (1976), Therapiewoche, 26:5722-5729
Lindberg, N.-O., (1970), Acta Pharm. Svecica, 7:23-28
Waller, A. R., (1985), Arnzeim.-Forsch./Drug Res., 35:489-492
Mosher, L. R., (1970), Am. J. Psychiat., 126:1290-1296
Abramson, D. I. et al., (1940), Am. J. Med. Sci., 200:96-102
Popkin, R. J., (1939), Am. Heart J., 18:697-704
Condorelli, L., (1964), in Niacin in Vascular Disorders and Hyperlipemia, R. Altschul (ed.), pp. 156-207
Andersson, R. G. G. et al., (1977), Acta Pharmacol. et Toxicol., 41:1-10
Svedmyr, N. et al., (1969), Clin. Pharmacol. Therapeut., 10:559-570
Bechgaard, H. and Jespersen, S., (1977), J. Pharmaceut. Sci., 66:871-872
Nickerson, M., (1975), The Pharmacological Basis of Therapeutics, Chapter 34, L. S. Goodman and A. Filman (eds.), pp. 745-760
Stella, V. J. et al., (Feb. 1978), Kans. Pharmacy, pp. 12-13
Levy, G., (1963), in Salicylates, an International Symp., Dixon et al. (eds.), pp. 9-17
Koysooko et al., (1974), Clin. Pharmacol. Therapeut., 15:454-460
Levy, G. et al., (1974), Pediatrics, 53:873-876
Hendeles, L. et al., (1985), Chest, 88:103S-111S
Piafsky, K. M. and Ogilvie, R. I., (1975), New Engl. J. Med., 292:1218-1222
Brattsand, R. and Harthon, L., (1975), Acta Pharmacol. Toxicol., 36:203-214
Cadwallader, D. E., (1971), Biopharmaceutics and Drug Interactions, (Roche Laboratories, Nutley, N.J.), p. 4